Early-stage study supports value proposition of Pulmatrix's PUR0200; shares ahead 5%

|By:, SA News Editor

Nano cap Pulmatrix (PULM +5.1%) is up on almost triple normal volume in response to results from a Phase 1 clinical trial assessing lead candidate PUR0200 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

PUR0200 achieved a similar therapeutic effect to Boehringer Ingelheim's Spiriva HandiHaler (tiotropium bromide) Inhalation Spray at an 83% lower dose with more than 30% less plasma drug exposure.

The value proposition of PUR0200, an improved inhaled tiotropium bromide, is enhanced efficacy by virtue of its iSPERSE dry powder technology which travels more easily into the lungs.

The company is co-developing PUR0200 with Vectura Group plc (OTCPK:VEGPF) for the U.S. market.

Previously: Pulmatrix teams up with Vectura to develop COPD candidate PUR0200; shares down 3% (Sept. 6, 2017)

Subscribe for full text news in your inbox